Yu-Wei Zhou

Yu-Wei Zhou

Auto-generated profile, based on publicly available information

Yu-Wei Zhou

State Key Laboratory of Pharmaceutical Biotechnology, National Resource Center for Mutant Mice, Department of Gastroenterology of Nanjing Drum Tower Hospital, and Suqian Scientific Research Institute, Medical School of Nanjing University, Nanjing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YZYu-Wei Zhou
Yu-Wei Zhou
JSJie Sun
Jie Sun
YWYe Wang
Ye Wang
CCCai-Ping Chen
Cai-Ping Chen
TTTao Tao
Tao Tao
MZMin-Sheng Zhu
Min-Sheng Zhu
Both chronic obstructive pulmonary disease (COPD) and asthma are severe respiratory diseases. Bitter receptor–mediated bronchodilation is a potential therapy for asthma, but the mechanism underlying the agonistic relaxation of airway smooth muscle (ASM) is not well defined. By exploring the ASM relaxation mechanism of bitter substances, we observed that pretreatment with the bitter substances nearly abolished the methacholine (MCh)-induced increase in the ASM cell (ASMC) calcium concentration, thereby suppressing the calcium-induced contraction release. The ASM relaxation was significantly inhibited by simultaneous deletion of three Gα t proteins, suggesting an interaction between Tas2R and AChR signaling cascades in the relaxation process. Biochemically, the Gα t released by Tas2R activation complexes with AChR and blocks the Gα q cycling of AChR signal transduction. More importantly, a bitter substance, kudinoside A, not only attenuates airway constriction but also significantly inhibits pulmonary inflammation and tissue remodeling in COPD rats, indicating its modulation of additional Gα q -associated pathological processes. Thus, our results suggest that Tas2R activation may be an ideal strategy for halting multiple pathological processes of COPD.

15 July 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
XCXin Chen
Xin Chen
TQTian-Tian Qiu
Tian-Tian Qiu
YWYe Wang
Ye Wang
LXLi-Yang Xu
Li-Yang Xu
JSJie Sun
Jie Sun
MZMin-Sheng Zhu
Min-Sheng Zhu
Intractable functional constipation (IFC) is the most severe form of constipation, but its etiology has long been unknown. We hypothesized that IFC is caused by refractory infection by a pathogenic bacterium. Here, we isolated from patients with IFC a Shigella species — peristaltic contraction–inhibiting bacterium (PIB) — that significantly inhibited peristaltic contraction of the colon by production of docosapentenoic acid (DPA). PIB colonized mice for at least 6 months. Oral administration of PIB was sufficient to induce constipation, which was reversed by PIB-specific phages. A mutated PIB with reduced DPA was incapable of inhibiting colonic function and inducing constipation, suggesting that DPA produced by PIB was the key mediator of the genesis of constipation. PIBs were detected in stools of 56% (38 of 68) of the IFC patients, but not in those of non-IFC or healthy individuals (0 of 180). DPA levels in stools were elevated in 44.12% (30 of 68) of the IFC patients but none of the healthy volunteers (0 of 97). Our results suggest that Shigella sp. PIB may be the critical causative pathogen for IFC, and detection of fecal PIB plus DPA may be a reliable method for IFC diagnosis and classification.

20 November 2025 in Science
Verified
Journal Article
Closed access
ZJZhihui Jiang
Zhihui Jiang
YWYe Wang
Ye Wang
JGJianfeng Gong
Jianfeng Gong
XCXin Chen
Xin Chen
DHDong Hang
Dong Hang
MZMin-Sheng Zhu
Min-Sheng Zhu
Ulcerative colitis (UC) is a severe inflammatory bowel disease affecting millions of people worldwide, but the factors driving the condition are poorly understood. In tissue samples from individuals with UC, we found that macrophages were depleted from areas of the colon that did not yet exhibit overt epithelial inflammation. We hypothesized that toxins produced by bacteria could impair macrophages and that this could promote wider inflammation. We isolated a variant of Aeromonas genus from stool samples from UC patients, which we termed macrophage-toxic bacteria (MTB), because aerolysin secreted by MTB caused macrophage death. MTB colonized mice under pathogenic conditions and triggered colitis. Antibodies against aerolysin alleviated colitis induced by Aeromonas in mice. In a cohort, UC patients more frequently tested positive for Aeromonas than healthy controls did.